Nelkarmi Wins Accelerated FDA Approval for ALK-Positive Lung Cancer That Progressed After Alectinib or Two Earlier Drugs
The Food and Drug Administration has granted accelerated approval to Nelkarmi (neladalkib) for adults with advanced ALK-positive non-small cell lung cancer whose disease worsened after earlier targeted treatment, GSK announced Nov. 17. The approval came ahead of the FDA's Nov. 27 target date. The drug is approved for two groups.…